Litcius/Paper detail

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin

Julien Hadoux, Pauline Afchain, Thomas Walter, David Tougeron, Vincent Hautefeuille, Carole Montérymard, Véronique Lorgis, Frédéric Thuillier, Éric Baudin, Jean‐Yves Scoazec, Côme Lepage, Romain Desgrippes

2021Digestive and Liver Disease19 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEtoposideInternal medicineContraindicationClinical endpointRegimenRandomized controlled trialNeuroendocrine tumorsOncologyProgression-free survivalChemotherapySurgeryPathologyAlternative medicineNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesThyroid Cancer Diagnosis and Treatment
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin | Litcius